Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance
Kay H. M. Roumans, Lucas Lindeboom, Pandichelvam Veeraiah, Carlijn M. E. Remie, Esther Phielix, Bas Havekes, Yvonne M. H. Bruls, Martijn C.G.J. Brouwers, Marcus Ståhlman, Marjan Alssema, Harry P. F. Peters, Renée de Mutsert, Bart Staels, Marja‐Riitta Taskinen, Jan Borén, Patrick Schrauwen, Vera B. Schrauwen‐Hinderling
Abstract
Abstract Hepatic steatosis is associated with poor cardiometabolic health, with de novo lipogenesis (DNL) contributing to hepatic steatosis and subsequent insulin resistance. Hepatic saturated fatty acids (SFA) may be a marker of DNL and are suggested to be most detrimental in contributing to insulin resistance. Here, we show in a cross-sectional study design (ClinicalTrials.gov ID: NCT03211299) that we are able to distinguish the fractions of hepatic SFA, mono- and polyunsaturated fatty acids in healthy and metabolically compromised volunteers using proton magnetic resonance spectroscopy ( 1 H-MRS). DNL is positively associated with SFA fraction and is elevated in patients with non-alcoholic fatty liver and type 2 diabetes. Intriguingly, SFA fraction shows a strong, negative correlation with hepatic insulin sensitivity. Our results show that the hepatic lipid composition, as determined by our 1 H-MRS methodology, is a measure of DNL and suggest that specifically the SFA fraction may hamper hepatic insulin sensitivity.